IDEAYA Biosciences, Inc. · NASDAQ:IDYA
IDEAYA Biosciences — Investor Presentation (November 2022)
31 slides from IDEAYA Biosciences's investor presentation, Nov 8, 2022
Slide 1: IDEAYA Biosciences
November 2022 NASDAQ: IDYA IDEAYA Biosciences Improving Lives Through Transformative Precision Medicines
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of IDEAYA Biosciences, Inc. (the “Company”) and involve known and unknown risks, uncertainti
Slide 3: IDEAYA Biosciences Highlights
IDEAYA Biosciences Highlights Leading Synthetic Lethality (SL) focused biotechnology company advancing transformative precision medicine therapies for cancer patients • Broad Pipeline of Key Emerging Targets including • 2022 / 2023 Catalysts clinical stage darovasertib (PKC) and IDE397 Darovaserti
Slide 4: Synthetic Lethality
Synthetic Lethality The Next Frontier in Precision Medicine Oncology Synthetic Lethality provides a powerful approach to discover novel precision medicine therapies with patient biomarkers, including MTAP-deletion (~15% of solid tumors), BRCA/HRD (Breast, Prostate, Ovarian), and high-MSI (15% GI Can
Slide 5: IDEAYA's Precision Medicine Oncology Pipeline
IDEAYA’s Precision Medicine Oncology Pipeline Building the Industry Leading Synthetic Lethality Focused Biotechnology Company Precision Medicine Pipeline Modality/Indication Biomarker Preclinical IND Enabling Phase 1 Phase 2 Program Goals Collaborations Commercial (IDEAYA) +cMET1 Combination Daro +
Slide 6: IDEAYA Leadership Team and Scientific Advisory Board
IDEAYA Leadership Team and Scientific Advisory Board Experienced Team & Scientific Thought Leaders in Precision Medicine Oncology IDEAYA Executives & R&D Leadership Yujiro Hata, M.B.A. Michael White, Ph.D. Paul Stone, J.D. Jason Throne, J.D. President, Chief Executive Officer, Director SVP, Chief Sc
Slide 7: IDEAYA Synthetic Lethality Platform
IDEAYA Synthetic Lethality Platform Fully-Integrated Target, Biomarker, Drug Discovery and Translational Capabilities Translational Research and Opportunity Expansion Drug Discovery and Genomics – DNA and RNA Analysis Pharmacological Validation Proteomics – Protein Expression Profiling SL Target & B
Slide 8: IDEAYA Synthetic Lethality Platform
IDEAYA Synthetic Lethality Platform Synthetic Lethality Target and Biomarker Discovery and Validation Synthetic Lethality Target Discovery & Validation Platform IDEAYA SL Platform integrates extensive proprietary and public data sets with orthogonal and complementary content Bioinformatic analysis e
Slide 9: IDEAYA Synthetic Lethality Drug Discovery Platform
IDEAYA Synthetic Lethality Drug Discovery Platform Structure-Based Drug Design & Proprietary Chemical Library Enable “Hard to Drug” Targets Structural Biology & Structure Based Drug Design INQUIRETM Proprietary Chemical Library Full suite of capabilities in structural biology, Expert-curated HTS lib
Slide 10: IDEAYA Synthetic Lethality Pipeline Strategy
IDEAYA Synthetic Lethality Pipeline Strategy Building the Industry Leading Synthetic Lethality Focused Biotechnology Company Focus on Potential First-in-Class Synthetic Lethality Programs to Enable Breakthrough Therapies Patient Impact: Potential First-in-Class / Best-in-Class Significant Opportunit
Slide 11: Darovasertib + Crizotinib – Phase 2 Synthetic Lethal Combination
Darovasertib Darovasertib + Crizotinib – Phase 2 Synthetic Lethal Combination Potential First-in-Class and Best-in-Class in MUM, Adjuvant UM and Other GNAQ/11 Tumors PKC + cMET Synthetic Lethal Discovery Preclinical Synergy Clinical Phase 1 Data Association * * Darovasertib + Crizotinib Synergy in M
Slide 12: Daro + Crizo Combo in Comparatively High-Risk, Poor Prognosis Population
Daro + Crizo Combo in Comparatively High-Risk, Poor Prognosis Population Disease Burden Significantly Higher in Both Any-Line and First-Line MUM Population+ IDE196-001 Study* Tebentasfusp Baseline Characteristics Darovasertib + Crizotinib Phase 3# Any-Line n=37 (%) First-Line n=8 (%) n=252 (%) < 65
Slide 13: Darovasertib + Crizotinib – Clinical Experience in Heavily Pretreated MUM
Darovasertib + Crizotinib – Clinical Experience in Heavily Pretreated MUM Observed Unprecedented ORR% and DCR% with Potential First-Line Differentiation First-Line MUM (n=8 Evaluable): 50% ORR with 75% DCR First-Line MUM * Evaluable (n=8) Any-Line MUM (n=35 Evaluable): 31% ORR with 83% DCR ORR (4/8)
Slide 14: Darovasertib + Crizotinib Combo Phase 2 Clinical Efficacy
Darovasertib + Crizotinib Combo Phase 2 Clinical Efficacy Encouraging mPFS and mDOR in 1L and Any-Line MUM versus historical data in MUM Darovasertib + Crizozotinib Any-Line MUM (n=35) Clinical Efficacy Summary in Any-Line and First-Line MUM Median Study Follow-Up * • Any-Line: 7.8 months • First-Li
Slide 15: Darovasertib + Crizotinib First-Line MUM Combo Efficacy
Darovasertib + Crizotinib First-Line MUM Combo Efficacy Examples of Confirmed PRs with Significant Tumor Shrinkage in First-Line MUM Patients First-Line MUM Patient First-Line MUM Patient • 40+ year old patient with ongoing response at 12 months • 50+ year old patient with ongoing response at 5 mont
Slide 16: Darovasertib + Crizotinib Synthetic Lethality Combination Therapy
Darovasertib + Crizotinib Synthetic Lethality Combination Therapy Differentiated Clinical Efficacy in MUM+ ESMO 2022: IPI + Nivo Combo in HLA-A2-0201 MUM reports ~6% ORR (2 PRs out of 33 patients)++ Darovasertib + Crizotinib Cabozantinib Selumetinib + Dacarbazine Tebentafusp Target / Mechanism PKC +
Slide 17: Darovasertib + Crizotinib Clinical Development Plan in First-Line MUM
Darovasertib + Crizotinib Clinical Development Plan in First-Line MUM Targeting Potential Registration Enabling Trial Initiation in Q1 20231 Key Considerations Single-Arm Phase 2 Randomized Integrated Phase 2/3 - Strategic Implications • Technical / Regulatory POS Single-Arm Phase 2 Trial (Expand On
Slide 18: Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma
Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma Preliminary Clinical Proof-of-Concept Supports Evaluation of UM Expansion Opportunity MUM Patients with Intact Primary Daro Monotherapy Daro + Crizo Combination Preliminary (Neo)Adjuvant UM Clinical PoC Phase 2 Study for (Neo)Adujvant UM 1 Bas
Slide 19: Uveal Melanoma and MUM Treatment Paradigm
Uveal Melanoma and MUM Treatment Paradigm US/EU Annual Incidence and Prevalence Darovasertib Monotherapy – Neoadjuvant UM Uveal Melanoma (UM) Patient Clinical Approach: administer darovasertib as a Adjuvant Neoadjuvant neoadjuvant therapy to reduce ocular tumor size Small and Medium Size Tumors (~80
Slide 20: MAT2A Inhibition is Synthetic Lethal with MTAP Deletion
MAT2A MAT2A Inhibition is Synthetic Lethal with MTAP Deletion MTAP Deletion Prevalence ~15% of all Solid Tumors MTAP-MAT2A Synthetic Lethality Biology MTAP Deletion Prevalence Methionine Cancer Type N MTAP Deletions (%) MTAP Glioblastoma 592 41 MAT2A is key enzyme that Mesothelioma 87 32 produces SA
Slide 21: IDE397: PDX Study of >40 MTAP-/- Models in Multiple Indications
IDE397: PDX Study of >40 MTAP-/- Models in Multiple Indications Monotherapy Tumor Regressions & Significant TGI Across Multiple Solid Tumor Types NSCLC and Bladder Cancer MTAP-/- PDX Models Panel Study of >40 MTAP-/- PDX Models NSCLC PDX Model Bladder PDX Model 150 1200 Tumor Growth Inhibition (%) V
Slide 22: IDE397 Clinical Data Summary – Monotherapy Dose Escalation Cohorts
IDE397 Clinical Data Summary – Monotherapy Dose Escalation Cohorts ctDNA Molecular Response demonstrates Tumor Pharmacodynamic Modulation Molecular Response Waterfall (Baseline to C2D1) IDE397 Ph 1 Samples - Comprehensive genomic profiling platform for clinical have Higher Tumor 100 586 135 97 devel
Slide 23: Clinically Evaluating Multiple MAT2Ai Rational Combination Strategies
Clinically Evaluating Multiple MAT2Ai Rational Combination Strategies Combination Strategies based on Mechanistic Hypothesis and Preclinical Efficacy IDE397 Novel Combinations Maximal Pathway Methionine Suppression * + MTA-Cooperative PRMT5i IDE397 IDE397 + Pemetrexed (NSCLC MTAP-/- CDX Model) (NSCL
Slide 24: IDE397 Phase 1/2 Clinical Development Plan
IDE397 Phase 1/2 Clinical Development Plan Evaluation of Monotherapy Expansion and Combinations IDE397 Development Candidate – Clinical Profile • Exposure-Dependent Pharmacokinetic (PK) Profile with low Cmax:Cmin • Monotherapy Expansion at Projected Clinically Active Dose * • Robust, Exposure-Depend
Slide 25: PARG Synthetic Lethality Program
PARG PARG Synthetic Lethality Program Targeting IND Q4 2022 for Development Candidate IDE161 PARG Biology IDE161 Drug Discovery and Profile Novel Target in Clinically Validated Pathway • Structurally-Based Drug Design Poly(ADP-ribose) glycohydrolase (PARG) regulates DNA repair • IDE161 is a potent,
Slide 26: IDE161 Cell Panel Activity Informs Selection of Predictive Biomarkers
IDE161 Cell Panel Activity Informs Selection of Predictive Biomarkers HRD Cell Lines are Selective Sensitivity to IDE161 Cellular Response Profiles inform Mechanistic Basis - Multiple Endogenous HRD Cell Lines are Selectively Sensitive PARGi Sensitivity within and Beyond HRD to IDE161 vs PARPi PARPi
Slide 27: HRD Models are Sensitive to PARGi
Homologous Recombination Deficient (HRD) Models are Sensitive to PARGi Observed PARGi Activity Distinct to PARP Inhibition in Breast, Gastric and Ovarian Models Robust activity in HRD PDX setting Regression in PARPi refractory models Defense against acquired resistance * BRCAmBreast Breastcancer Can
Slide 28: IDE161 Demonstrates Favorable Efficacy and ADME/PK Profile
IDE161 Demonstrates Favorable Efficacy and ADME/PK Profile Preliminary Safety Data Suggests Differentiated Target Product Profile vs PARP Inhibitors Observed Tumor Regressions in Robust PD Modulation and Sustained PK PARP-Resistant HRD Model Vehicle Vehicle Mean Tumor Volume (mm3) ± S.E.M. IDE161 10
Slide 29: Pol Theta Helicase Synthetic Lethality Program
Pol Theta Pol Theta Helicase Synthetic Lethality Program Targeting First-in-Human Phase 1 Clinical Trial Initiation in H1 2023 Clinical Development Strategy Pol Theta Helicase In Vivo Activity BRCA 1/2 Clinical Reversions Pol Theta Helicase PARP Pol Theta Helicase Inhibitor + PARPi BRCA Reversions M
Slide 30: Werner Helicase Synthetic Lethality Program
Werner Werner Helicase Synthetic Lethality Program Targeting Development Candidate in 2023 Werner Helicase Synthetic Lethal with High-MSI Werner Inhibitor Cellular PD and In Vivo Efficacy WRN inhibitor PD and in vivo Werner Syndrome Helicase is efficacy with Required for the Survival of ~100% TGI an
Slide 31: Synthetic Lethality Focused Precision Medicine Oncology Biotech
Synthetic Lethality Focused Precision Medicine Oncology Biotech First-in-Class Synthetic Lethality Pipeline and Leading SL Platform Broad Pipeline of Potential First-in-Class Synthetic Lethality Programs with large addressable patient populations in major solid tumor types, including Phase 2 clinica
IDEAYA Biosciences — Investor Presentation (November 2022) on 6ix